Imaging Agents to Monitor the Distribution of Therapies Delivered to the Brain
Background:
The National Institute of
Neurological Disorders and Stroke (NINDS) seeks a commercial
collaborator to work with NINDS in the development and
commercialization of surrogate markers for monitoring the spatial
distribution of therapeutic substances by MRI or CT that have been
administered to tissue of the brain using Convection Enhanced
Delivery (CED).
Technology:
The macromolecular imaging agents
have clearance properties that mimic the pharmacokinetic properties
of co-administrated drugs, so as to be useful in quantifying the
range and dosage level of therapeutic drugs using MR imaging.
Potential Areas of
Application:
Delivery of various therapeutic
compounds that otherwise would not pass the blood brain barrier
Main Advantages of
Technology/Invention:
- Increases the breadth of compounds available for treatment of
diseases and disorders of the brain.
- Improves the utilization of CED in delivering drugs to the
brain.
Current State of
Development:
- CED in use by multiple research and medical facilities
- Non-human primate imaging studies completed
- cGMP-grade compound in development
Further R&D
Required:
- Development of additional markers
- Additional clinical trials
IP Status:
Patent pending
Contact
Information:
Laurie Arrants
Technology Development Coordinator, NINDS
Phone: 301-435-3120
E-mail: ArrantsL@ninds.nih.gov
Reference: #211 LA
Updated 04/03/2008
This opportunity is also listed under the following categories: